Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Current Assets: 2019-2025

Historic Current Assets for Keros Therapeutics (KROS) over the last 6 years, with Sep 2025 value amounting to $719.3 million.

  • Keros Therapeutics' Current Assets rose 30.30% to $719.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $719.3 million, marking a year-over-year increase of 30.30%. This contributed to the annual value of $588.9 million for FY2024, which is 69.57% up from last year.
  • As of Q3 2025, Keros Therapeutics' Current Assets stood at $719.3 million, which was down 1.84% from $732.8 million recorded in Q2 2025.
  • In the past 5 years, Keros Therapeutics' Current Assets ranged from a high of $759.5 million in Q1 2025 and a low of $222.4 million during Q2 2022.
  • Moreover, its 3-year median value for Current Assets was $463.1 million (2024), whereas its average is $508.8 million.
  • As far as peak fluctuations go, Keros Therapeutics' Current Assets soared by 337.28% in 2021, and later fell by 9.67% in 2022.
  • Over the past 5 years, Keros Therapeutics' Current Assets (Quarterly) stood at $251.4 million in 2021, then rose by 13.65% to $285.8 million in 2022, then rose by 21.53% to $347.3 million in 2023, then surged by 69.57% to $588.9 million in 2024, then soared by 30.30% to $719.3 million in 2025.
  • Its last three reported values are $719.3 million in Q3 2025, $732.8 million for Q2 2025, and $759.5 million during Q1 2025.